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OBJECTIVES: To evaluate the safety and efficacy of endovascular intervention with angioplasty and stent
placement in patients with transplant renal artery stenosis.
METHODS: All patients diagnosed with transplant renal artery stenosis and graft dysfunction or resistant
systemic hypertension who underwent endovascular treatment with stenting from February 2011 to April 2016
were included in this study. The primary endpoint was clinical success, and the secondary endpoints were technical
success, complication rate and stent patency.
RESULTS: Twenty-four patients with transplant renal artery stenosis underwent endovascular treatment, and
three of them required reinterventions, resulting in a total of 27 procedures. The clinical success rate was 100%.
All graft dysfunction patients showed decreased serum creatinine levels and improved estimated glomerular
filtration rates and creatinine levels. Patients with high blood pressure also showed improved control of sys-
temic blood pressure and decreased use of antihypertensive drugs. The technical success rate of the procedure
was 97%. Primary patency and assisted primary patency rates at one year were 90.5% and 100%, respectively.
The mean follow-up time of patients was 794.04 days after angioplasty.
CONCLUSION: Angioplasty with stent placement for the treatment of transplant renal artery stenosis is a safe
and effective technique with good results in both the short and long term.
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’ INTRODUCTION
Renal transplantation is an important therapeutic option
for patients with end-stage chronic kidney disease, and it
is associated with increased rates of survival and a better
quality of life in these patients (1).
However, certain complications following transplantation
may affect the graft and patient survival. With advances in
immunosuppressive drugs, graft loss due to rejection has
decreased to rates of 20-30%. Additionally, other complica-
tions have also gained major importance (2). Transplant renal
artery stenosis (TRAS) is the most common vascular compli-
cation that may occur after transplantation, affecting 1-23%
of patients (3).
Vascular alterations in the renal artery of the transplanted
kidney may be either asymptomatic and/or associated with
cases of refractory hypertension during clinical treatment
and/or graft dysfunction (6), and they are typically related to
decreases in overall survival rates of patients who undergo
renal transplantation (4-7).
The benefits of endovascular intervention for the correc-
tion of TRAS remain under debate, however, and few results
are currently available in the literature. It is believed that this
technique may aid in the control of high blood pressure
and may improve renal function, contributing substantially
to better graft and patient survival (3,8-10).
This study aimed to evaluate the safety and efficacy of
endovascular intervention with angioplasty and stent place-
ment in patients with TRAS.
’ MATERIALS AND METHODS
Study design
This was a retrospective study carried out in the Depart-
ment of Interventional Radiology and Nephrology, and itDOI: 10.6061/clinics/2017(12)09
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was approved by the Ethics and Research Committee of
the institution.
Patients and eligibility
All patients diagnosed with TRAS who underwent endo-
vascular treatment from February 2011 to April 2016 were
included in this study.
The diagnosis of TRAS was confirmed via Doppler ultra-
sonography (peak systolic velocity4200-250 cm/s, resistance
index 40.8, pulsatility index 41.5, stenosis/prestenotic
velocity gradient 42:1, tardus parvus in systolic acceleration
40.1 seconds, or acceleration in renal hilum 4100 cm/s).
All patients included in the study had either graft dysfunc-
tion or resistant systemic hypertension. Graft dysfunction was
defined as delayed graft function in kidney transplants assessed
by measuring the creatinine level and estimated glomerular
filtration rate (eGFR) using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) equation, while resistant
systemic hypertension was defined as blood pressure 4140/
90 mmHg, despite treatment with antihypertensive drugs.
Endovascular procedure
Patients with stenosis diagnosed using Doppler ultrasono-
graphy underwent an angiographic study. The access route
for the procedures was either the ipsilateral or contralateral
common femoral artery. Pelvic and transplanted renal artery
angiograms were performed for anatomical evaluation and
lesion quantification.
Following angiographic confirmation of stenosis, systemic
heparinization was performed with unfractionated heparin,
followed by transposition of the lesion with a 0.014 guide-
wire. All cases were treated with stent implantation: in one
case, a self-expanding stent was used, and in the other cases,
expandable balloon stents, such as Visions Cobalt Chro-
mium (Abbott Laboratories, Chicago, IL, USA), TAXUSt
Libertét (Boston Scientific Corporation, Natick, MA, USA),
Expresst Vascular Stent (Boston Scientific Corporation),
Dynamic Stent (BIOTRONIK, Berlin, Germany), and/or
Direct-Stents (InSitu Technologies, St. Paul, MN, USA),
were used. The materials were used without standardization
at the discretion of the interventional physician. At the end of
the procedure, hemostatic devices, such as the Perclose
Proglide (Abbott) and/or the StarClose (Abbott) devices,
were used at the puncture site.
Clinical variables and outcomes
Information such as sex, age, risk factors, technical data
related to transplantation (i.e., from both the donor and
recipient), laboratory tests, diagnostic methods, anatomical
pattern of stenosis, and technical details related to treatment
(e.g., contrast volume, tomographic imaging, material used,
treatment methods, postoperative assessment with arterial
patency, blood pressure control, renal function, and survival)
was collected. Renal function was determined using serum
creatinine levels, and the eGFR was obtained in the pre-
operative and postoperative periods (i.e., 48 hours prior and
30, 60, and 90 days after) via the CKD-EPI equation.
Technical success was defined as revascularization with
stent implantation without complications and/or with com-
plete absence of or o30% residual stenosis. Clinical success
was defined as improved renal function (both creatinine
levels and eGFR) in cases of renal dysfunction or improved
blood pressure control, with a reduction in the use of
antihypertensive drugs, in patients with arterial hyperten-
sion secondary to TRAS.
Statistical analysis
The quantitative characteristics evaluated in the patients
are described using summary measures (i.e., mean, standard
deviation, median and quartiles), and the qualitative vari-
ables are described using absolute and relative frequencies.
The creatinine levels were compared preoperatively using
the lowest value at follow-up via the paired Wilcoxon test.
Blood pressure controls, measured mainly by the total number
of medications used, were also compared between the pre-
operative and follow-up periods using the paired Wilcoxon
test. A Kaplan-Meier analysis was used to determine the
graft survival curve and to evaluate patency rates and the
probability of occurrence of events. A p-value p0.05 was
considered significant.
’ RESULTS
From February 2011 to April 2016, 29 patients who were
diagnosed with TRAS using Doppler ultrasonography
underwent angiography. Twenty-four of these cases under-
went endovascular treatment, and three required reinterven-
tions, resulting in a total of 27 procedures.
Five patients underwent only diagnostic angiography with-
out intervention and, therefore, were excluded from the final
analysis. In four of these cases, angiography showed only mild
stenosis with no flow change, while the remaining patient
demonstrated severe stenosis and thrombosis of segmental
branches, with changes in the parenchymal phase of the
angiographic study. No treatment approach was indicated
for this patient.
Patient profile
The profile of the study population and the data con-
cerning the renal grafts, as well as the surgical procedures
used, are described in Table 1 and Table 2.
Table 1 - Demographic Profile of Patients.
Variable N %
Sex
Male 15 68.2
Female 7 31.8
Hypertension
No 2 9.1
Yes 20 90.9
DM
No 16 72.7
Yes 6 27.3
CVD
No 18 81.8
Yes 4 18.2
Smoking*
No 17 81.0
Yes 4 19.0
Dyslipidemia
No 13 59.1
Yes 9 40.9
Death
No 20 90.9
Yes 2 9.1
Total 22 100
* Information was not available for all patients.
DM: Diabetes mellitus.
CVD: Cardiovascular disease.
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Of the 24 patients who were diagnosed with TRAS and
underwent endovascular treatment, 21 had graft dysfunction
and 3 had resistant systemic hypertension. Three of these
patients underwent re-stenosis due to graft dysfunction.
All arterial anastomoses were performed on the iliac arteries.
In one case, anastomosis was performed on the internal iliac
artery (4.5% of cases), while anastomosis was performed on
the external iliac artery in the remaining cases.
Of the 24 grafts used in the study, six (25%) grafts were
from living donors. Furthermore, only one graft used
during a reintervention was from a living donor (33% for
reintervention).
Technical and clinical success
The technical success rate of the procedure was 97%. The
mean pretreatment and post-treatment stenosis rates were
79.40% and 2.40%, respectively. No relationship between the
postoperative period and the stenosis site was found (Table 3).
The clinical success rate was 100%. All patients showed
decreased serum creatinine levels (Figure 1) and improved
eGFR and creatinine levels (Figure 2), with a statistically
significant improvement noted following 30 days of treat-
ment (po0.001), which was further maintained after 60
and 90 days (Table 4). Patients with high blood pressure
also showed improved control of systemic blood pressure
and decreased use of antihypertensive drugs (po0.008)
(Table 5).
Procedures and patency
The median diameter and length of the stents used were
5 and 12 mm, respectively (Table 6). Intraoperative tomo-
graphic imaging was performed in 37% of the cases, with no
significant increase in contrast volume or radioscopy time
noted (Table 7).
The primary patency and assisted primary patency rates in
one year were 90.5% and 100%, respectively. Both rates were
maintained until the end of the study, considering the mean
follow-up time of patients of 794.04 days after angioplasty
(Figure 3). During the evaluation period, two patients died
due to non-renal causes; their grafts were patent and func-
tioned properly for 587 days and 1,023 days, respectively.
Re-interventions
Of the three cases requiring re-intervention, one was
due to in-stent re-stenosis after two months of treatment
(Dynamic Stent 5 12, BIOTRONIK, Berlin, Germany).
In this case, the patient’s renal dysfunction remained after
stent placement. A new Doppler ultrasonography exam
showed increased resistance in the renal artery. Angioplasty
Table 3 - Evaluation of the Stenosis Site.
Stenosis site Days until TRAS
Mean SD Median Minimum Maximum N p
Anastomosis 190.23 212.82 135 13 706 13 0.794
Distal 138.56 49.81 130 86 246 9
Total 169.09 165.84 132.5 13 706 22
Mann-Whitney U test.
Table 2 - Data Analysis Associated with the Renal Graft and Surgical Procedure.
Variable Mean SD Median Minimum Maximum N
Age 49.9 14.3 51.5 20.0 75.0 22
Days until TRAS 169.1 165.8 132.5 13.0 706.0 22
Donor age 42.6 13.9 43.5 19.0 69.0 22
Graft survival rate 689.5 462.9 575.5 115 2069 22
Radioscopy time (min) 20.4 11.8 16.1 7.2 56 18
Contrast volume (ml) 185.1 52.0 180.0 100 300 17
Figure 1 - Preoperative and postoperative mean serum creatinine
levels (in days).
Figure 2 - Preoperative and postoperative mean creatinine
clearance rates (CKD-EPI) (in days).
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using an IntraStents balloon catheter (Covidien, Dublin,
Ireland) was subsequently performed.
The second case of re-intervention was due to graft dysfunc-
tion. Three renal arteries were transplanted, with one branch
initially treated with a stent (Visions Cobalt Chromium
3.0 15, Abbott Laboratories) and two branches treated with
a pharmacological balloon catheter (FALCON 3 40). Dur-
ing the follow-up, five months after angioplasty, the patient’s
serum creatinine levels were found to have increased, and a
stent was placed in the two branches initially treated with a
balloon (Visions Cobalt Chromium 2.0 28, Abbott Labora-
tories), with progression occurring favorably.
The third case underwent re-intervention initially due to
graft dysfunction. The patient underwent endovascular treat-
ment with stent placement (Dynamic Renal Stent, BIOTRO-
NIK, Berlin, Germany) and, after an initial improvement of
symptoms, exhibited further worsening of renal function.
A second intervention was performed in which renal stent
patency was observed, although with dissection of the left
Table 4 - Variation in Serum Creatinine Levels and Creatinine Clearance Rates (CKD-EPI) throughout the Study.
Variable Time Mean SD Median Minimum Maximum N p
Creatinine Preoperative period 3.05 1.61 2.76 1.34 6.88 22 o0.001
Immediate postoperative period 2.56 1.49 2.01 1.27 7.59 22
30 days 1.73 0.47 1.78 0.89 3.03 21
60 days 1.78 0.59 1.68 0.67 2.94 20
90 days 1.62 0.53 1.68 0.65 3.03 21
End of follow-up 1.67 0.68 1.68 0.80 3.49 22
CKD-EPI Preoperative period 28.39 17.18 23.26 7.48 68.15 22 o0.001
Immediate postoperative period 33.49 15.64 31.84 6.93 63.00 22
30 days 44.92 15.06 40.85 21.47 76.57 21
60 days 46.71 20.78 42.41 23.62 103.90 20
90 days 51.41 23.38 41.11 21.47 107.78 21
End of follow-up 51.91 21.71 45.50 18.00 100.00 22
Bonferroni correction.
Table 5 - Preoperative and Postoperative Quantitative Analysis of Antihypertensive Drugs used by Patients.
Variable Mean SD Median Minimum Maximum N p
Preoperative antihypertensive drugs 2.09 1.15 2 0 4 22 0.008
Postoperative antihypertensive drugs 1.59 1.05 1.5 0 4 22
Wilcoxon signed-rank test.
Table 6 - Evaluation of Patency Times and Stent Sizes.
Variable Mean SD Median Minimum Maximum N
Patency time (days) 488.91 450.09 345 21 1830 22
Mean diameter of stents 4.89 1.46 5 2 8 19
Mean length of stents 12.68 7.14 12 0 28 22
Table 7 - Evaluation of Contrast Volume in Milliliters and Scoping Time Related to Cone-beam CT.
Variable CBCT Mean SD Median Minimum Maximum N p
Contrast volume (ml) No 195.11 58.01 200 130 300 9 0.481
Yes 173.75 45.336 175 100 250 8
Total 185.06 51.986 180 100 300 17
Radioscopy time (min) No 21.536 13.3556 17.765 10.5 56 10 0.762
Yes 19.08 10.2365 16.06 7.2 34.5 8
Total 20.444 11.7964 16.125 7.2 56 18
Mann-Whitney U test.
Figure 3 - Patency probability following the procedure (in days).
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iliac artery, which was deemed to be a possible complication
related to the first procedure. The patient underwent place-
ment of a self-expanding stent (Everflext, Covidien, Dublin,
Ireland) in the iliac artery, and renal function improved.
Complications
No immediate complications were observed after the pro-
cedure. A case of dissection of the common iliac artery with
extension to the external iliac artery was diagnosed 30 days
after the initial procedure but was resolved with a self-
expanding stent.
’ DISCUSSION
This retrospective study was carried out to evaluate the
impact of endovascular treatment in patients diagnosed
with TRAS, which was proven to be an effective and safe
procedure.
The prevalence of TRAS observed in our study was 5.6%,
similar to that found in other studies (3,5,6,11). Our analysis
revealed renal dysfunction, associated with abnormalities in
Doppler ultrasonography, to be a major clinical presentation
and to be present in 90% of cases, a finding similar to that in
other reviews (4,5).
A higher peak systolic velocity and velocity gradient
between the transplanted renal artery and the iliac artery is a
criterion of higher sensitivity in Doppler ultrasonography
for TRAS (6). Although some authors cited the presence of
a peak systolic pressure gradient410% or stenosis450% in
angiography as an indication for intervention, no consensus
has been established in the literature regarding stenosis
ranges and/or standards for intervention (12). In this study,
Doppler ultrasonography was used as a screening method in
patients with a clinical presentation of TRAS.
The anastomosis site and onset may be related to different
risk factors. The mean onset of TRAS in our study was
169 days, and the most common site of stenosis was the
anastomosis, which is similar to findings described in other
studies, and was present in more than half of the cases in this
study (4,6,13). This stenosis may be associated with mechan-
ical lesions of the blood vessels during organ recruitment
or the surgical procedure and was found to present early
after transplantation (14,15). The stenosis that occur later,
sometimes several years after transplantation, usually reflect
atherosclerotic disease and are also associated with rejection
and/or cytomegalovirus infection (4,5,16,17). In our study,
no relationship was found between the anastomosis site and
time of onset. A review of the medical records showed that
no vascular lesion was reported during organ recruitment or
the surgical procedure, although other changes not described
during the procedure, such as hyperflexion of blood vessels
and endothelial injury during graft perfusion, are related to
this type of stenosis.
The treatment of TRAS is crucial, as the presence of graft
dysfunction and/or high blood pressure may alter the renal
graft and compromise patient survival (10,18-20).
Concerning therapeutic options, clinical and medical care
is limited to patients with TRAS, stable renal function, and
non-significant lesions, while surgical intervention should be
reserved as a salvage option in cases in which angioplasty
is unsuccessful (9). Endovascular intervention, despite risks
such as renal artery disease, re-stenosis, thromboembolism
and complications related to the puncture site, may be
considered a first-line therapy for TRAS (9,21,22).
Our results are similar to those in the literature, which
describe a technical success rate ranging from 89 to 100%
(4,16,21,23). In our study, the technical success rate was 97%
and the clinical success rate was 100%.
Ngo et al. systematically reviewed 32 studies of TRAS and
found a clinical success rate between 65.5 and 94% (24).
Among the 28 studies that evaluated renal function, the
mean creatinine level reduced 0.45 mg/dL after 30 days and
0.82 mg/dL after six months. Estimated GFR was evaluated
in 11 studies, which showed an average gain of 8.6 mL/min/
1.73 m2 three months after endovascular intervention. Our
review showed that renal function significantly improved
following intervention, with values higher than those found
in these studies. The mean creatinine level decreased by
1.32 mg/dL and the eGFR increased by 16.53 mL/min/
1.73 m2 after 30 days. These values were maintained after
90 days, and a short-term improvement in renal function was
Figure 4 - A 51-year-old female patient with acute graft dysfunction. (A) Angiographic study showing severe renal artery stenosis
(arrow) in the segment distal to the anastomosis. (B) Control angiography after stenting, showing adequate positioning of an Expresst
Vascular Stent 618 (Boston Scientific Corporation, Natick, MA, USA) with successful lesion treatment.
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predictive in the long run. The mean follow-up of patients
was 794 days, and all of them maintained stable renal func-
tion until the end of the follow-up period. The maintenance
of satisfactory kidney function after transplantation is directly
related to the graft and patient survival rates, and we expect
that these factors may have an effect on our patients (18,19).
Among the patients undergoing treatment because of graft
dysfunction, three underwent intervention due to delayed
graft function (DGF), as they remained on dialysis even after
renal transplantation. All of them left dialysis and main-
tained adequate renal function after correction of TRAS,
which had an important effect on graft and patient survival
rate, as DGF is associated with poor outcomes (19,25).
Despite the heterogeneous results found following endo-
vascular treatment of TRAS with balloon catheters, studies
with stent placement showed that high blood pressure was
improved following this treatment, with a reduction of anti-
hypertensive drugs, which was also found in our study
(24,26). Adequate blood pressure control is very important,
as high blood pressure can result in a decreased graft
survival rate and left ventricular hypertrophy, the latter of
which is an independent risk factor for heart failure and
death in both the general population and renal transplant
recipients (20,27).
During follow-up, patency levels ranging from 63 to 82%
were described one year after endovascular treatment, with
a re-stenosis rate ranging from 10 to 36% (28). In our study,
a primary patency of 90.5% was reached after three months,
and assisted primary patency of 100% was achieved after two
years following angioplasty with a balloon-expandable stent.
In the literature, early complications are noted, including
bleeding, pseudoaneurysm formation, thrombosis, arterial
dissection, hematoma, and intimal flap, in approximately
10% of cases (6,29). In our experience, no cases of early
complications were reported; however, it was observed that
late complications occurred in 4% of patients, represented by
one cases of iliac artery dissection.
No randomized trials comparing multiple treatment tech-
niques for TRAS were found in the literature. This study is
limited mainly because it is not a multicenter retrospective
study, although our population was larger than that in many
studies found in the literature.
Based on our experience, we conclude that angioplasty
with stent placement for the treatment of TRAS is a safe and
effective technique for improving eGFR, serum creatinine
levels, high blood pressure control and graft survival rate,
with excellent results in both the short and long term.
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